<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The bcl-2 gene was first shown to be dysregulated in the majority of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in which a t(14;18) chromosomal translocation is present, but is also over-expressed in the absence of gene rearrangements in most cases of B-cell <z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (B-CLL) </plain></SENT>
<SENT sid="1" pm="."><plain>The bcl-2 oncoprotein is a regulator of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and the activity of this protein is opposed by bax, a homologous protein that accelerates the rate of cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>B-lymphocyte bcl-2 and bax protein levels were found to be significantly altered in B-CLL patients when compared to those of a <z:mpath ids='MPATH_458'>normal</z:mpath> control group </plain></SENT>
<SENT sid="3" pm="."><plain>Increased bcl-2/bax ratios were observed in both the treated and untreated patients when compared to those of <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="4" pm="."><plain>These alterations were particularly pronounced in those treated patients found to be clinically unresponsive to chemotherapy </plain></SENT>
</text></document>